Help for children with peanut allergy
Patches with peanut protein may reduce long-term risk of severe allergic reactions in children under four years of age
A large-scale international study with the participation of the University Hospital Frankfurt has now taken care of the youngest sufferers. It tested immunotherapy with peanut allergen-coated patches for children between one and three years of age with peanut allergy. With success: the reaction threshold was raised by a median of 900 mg of peanut protein (equivalent to three peanuts) after twelve months of therapy, while in the placebo group, which had only received "sham therapy", no median increase in the reaction threshold was observed.
Hope for children and families
"The study offers hope for young children with peanut allergy and for their families. Patch treatment has been shown to be effective and safe. A further study is now being conducted to investigate the efficacy and safety profile of the patch in four- to seven-year-old peanut allergy sufferers," explains PD Dr. Katharina Blümchen from the Department of Pediatrics and Adolescent Medicine at Frankfurt University Hospital, who was involved in the study. The editor of the New England Journal of Medicine likewise called the results "good news for young children with peanut allergy."
Prof. Dr. Jan-Henning Klusmann, Director of the Department of Pediatrics and Adolescent Medicine at Frankfurt University Hospital, added: "The results represent real progress in the treatment of young children with peanut allergy. They are also a sign of the first-class patient care in our Department of Pneumology, Allergology, Infectiology and Gastroenterology. The opportunity to participate in internationally pioneering studies means that children cared for here can receive advanced therapies in some cases years before the drug is actually officially approved."
High everyday suitability, low risk
Studies have shown that early intake of peanut in complementary feeding reduces the risk of developing peanut allergy later in life. Thus, the immune system appears to be highly malleable at an early age. Immunotherapies, in which those affected take small doses of the allergen daily, for example, in order to bring about desensitization and raise the reaction threshold, have so far only been approved for children and adolescents with peanut allergy over the age of four. With this therapy, families must adhere to sometimes elaborate intake schedules, and side effects can occur.
The current study therefore uses patches containing the allergen, which are applied once a day between the shoulder blades. These do not have to be removed even for bathing or swimming, making them easier to use in everyday life. The dose that the patch contains (250µg peanut protein) is further below, for example, the maintenance dose of oral immunotherapy (300 mg peanut protein), i.e. the amount that must be taken at least regularly for the therapy to have a sustained effect.
Study at 51 sites
The study was conducted at 51 sites in eight countries from 2017 to 2022, with 307 infants fully completing the study. Frankfurt was one of three sites in Germany. All subjects received a patch once a day for a year. In a good third, the patch was a placebo. All children were allergic at baseline to a dose of 300 mg of peanut protein or less - the equivalent of a single peanut.
The goal of the study was to raise this trigger dose to 1,000 mg if the children were allergic to more than 10 mg at baseline or to raise the trigger dose to 300 mg if the children initially reacted to 10 mg or less. This goal was achieved by 67 percent of children in the intervention group that received patches containing the allergen and 33.5 percent in the placebo group.
That improvement was also seen in the children with placebos is not unexpected. Studies show that about 29 percent of affected children outgrow their allergy by age six. However, the other results of the current study support the effectiveness of desensitization.
Significant improvement, few side effects
In the group where the patches actually contained the peanut protein, the median change in trigger dose was 900 mg, compared to 0 mg in the placebo group. In addition, in the intervention group, just over 37 percent of the children were able to consume a total of 3,444 mg of peanut protein in the oral provocation at the end of the study until an allergic reaction occurred. In the placebo group, the figure was only 10 percent.
So-called adverse events occurred in almost all children during the study period - i.e. also in the placebo group. The most common adverse events were skin reactions around the patch, although these decreased over time. A total of 23 systemic allergic reactions occurred - 19 in the group receiving the patch with peanut allergen and four in the placebo group. According to the assessment of the respective study physician, four of these were due to treatment with the peanut patch. This represents 1.6 percent of all reported adverse reactions in the intervention group. All of these reactions were mild or moderate. The study was therefore also able to demonstrate the safety of the patch therapy.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
Other news from the department science
Start-up Colossal Biosciences Joins Biorescue In Its Mission To Save The Northern White Rhino From Extinction
Colossal will assist the rescue mission by leveraging genome sequencing and gene editing methods to save the endangered species
"For the first time, we have systematically measured the size and abundance of cells across all major tissues and organs"
What's that smell? New gut microbe produces smelly toxic gas but protects against pathogens
Taurine-degrading bacteria influence intestinal microbiome
Wastewater treatment plants as drivers for the energy transition
Technical add-on module can, in principle, turn any wastewater treatment plant into a CO2 sink and decentralized methane production plant
At which age we are at our happiest
An evaluation of over 400 samples shows how subjective well-being develops over the course of a lifespan
New approach to testing for long Covid
Blood vessels in the eye altered with persistent coronavirus symptoms
Researchers create pioneering approaches for the detection of viral antigens
Sybodies: a revolution in biological recognition
New SARS-CoV-2 variant Eris on the rise
SARS-CoV-2 lineage EG.5.1 has an advantage at evading neutralizing antibodies
Does the human brain have an Achilles heel that ultimately leads to Autism?
CHOOSEn fate: one brain organoid’s tale on Autism
Co-crystal improves the water-solubility of ASA
This could benefit patients diagnosed with suspected acute myocardial infarction
Observing nanoparticles with unprecedented precision
Illuminated: Researchers investigate new physical phenomena on the nanoscale with microstructured fibers
Falling Walls announces Science Breakthrough of the Year 2023 laureates
“These outstanding breakthroughs will change the face of the world and impressively prove what ingenuity, curiosity and courage can achieve”
Most read news
Cells with an ear for music release insulin
For the first time, researchers are using music, including Queen's global hit "We will rock you," to stimulate insulin release from cells
"Anti-obesity drugs" normalises brain in obesity
Anti-obesity drug improves associative learning in people with obesity
Microbe of the Year 2023: Bacillus subtilis – for health and technology
Already, Bacillus subtilis is indispensable in many industries, and many more innovations are expected
Younger generation gets sick earlier and more often than older generation
In spite of their advanced age, they are in the middle of life, healthy, active and mentally alert – they are referred to as the “young old”
How sleep deprivation can harm the brain
Sleep deprivation decreases the amount of a factor that protects neurons
A whole new order of bacteria could hold the key to improving biogas production
The discovery was made by researchers from Germany, Spain and the Netherlands
How to inactivate common cold viruses
In the cold season, cold viruses are everywhere. But we can do something about it
New approach to testing for long Covid
Blood vessels in the eye altered with persistent coronavirus symptoms
How minimal genetic differences can turn healthy food into a deadly danger
You are what you eat - this old saying could take on a new dimension according to latest research results
More news from our other portals
Major breakthrough in the development of electric vehicle batteries
New study finds ways to suppress lithium plating in automotive batteries for faster charging electric vehicles
Blender Bites launches at Walmart USA
The products are to be introduced in about 1,600 stores across the country
Benchtop NMR spectroscopy can accurately analyse pyrolysis oils
More accessible analysis could help develop the potential of bio-oils as an alternative to fossil fuels
Clean water from fog
A property known as photocatalytic memory ensures that this also functions when skies are overcast and at night
Research shows table salt could be the secret ingredient for better chemical recycling
Table salt as the key to the plastics recycling revolution?
Green, sweet and crisp - New apple variety Pia41 approved
The apple bred at the Julius Kühn Institute receives variety protection
Graphene discovery could help generate hydrogen cheaply and sustainably
Microscopic insights into electrochemical interfaces
Sugar: Small increase in production despite record prices
EU sugar market more than in need of reform to keep medium-sized processing companies competitive
Scientists use quantum device to slow down simulated chemical reaction 100 billion times
What happens in femtoseconds in nature can now be observed in milliseconds in the lab
Green methanol for shipping and industry: € 10.4 Mio. for the "Leuna100" project
A consortium of two Fraunhofer institutes, DBI-Gastechnologisches Institut Freiberg, Technical University of Berlin and C1 makes industrial history at the Leuna site
Stanford study shows how the meat and dairy sector resists competition from alternative animal products
New battery holds promise for green energy
Redox-flow battery eliminates costly and inefficient membrane
Fondant under the magnifying glass
New insights into the properties of sweet coating: The results could be used to optimize the industrial production process in the future
Leipzig-based start-up converts CO₂ into green chemicals with patented plasma catalysis
CO₂ recycling as a useful complement to carbon capture and storage
A microchip for Parmigiano Reggiano cheese
Consorzio del Parmigiano Reggiano, p-Chip Corporation, and Kaasmerk Matec Partner to Launch Breakthrough in Food-Safe Digital Tracking Technology
Cleaning water with ‘smart rust’ and magnets
New method for pollutants such as crude oil, glyphosate, microplastics and hormones
A Second Life for Electric Car Batteries
Scientists develop a decision model for retired lithium-ion batteries